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Abstract
Objective + Candoxatrilat was used to raise atrial natriuretic factor (ANF) concentrations in patients with heart failure, and the effects on left ventricular systolic and diastolic function were studied to determine the contribution of peripheral and central mechanisms to the haemodynamic effects.
Design-This was a single blind, randomised comparison of + candoxatrilat and placebo in patients with mild heart failure. All patients received two intravenous doses of + candoxatrilat and two placebo doses on four consecutive days.
Setting-A teaching hospital department of cardiology.
Patients-Six men (mean age 52 years) with mild heart failure (New York Heart Association class II) due to ischaemic heart disease (four patients) or dilated cardiomyopathy (two patients) were included. Mean ejection fraction was 37*5% and mean peak oxygen consumption was 204 ml/min/kg.
Main outcome measures-Plasma ANF concentrations, haemodynamic indices and left ventricular diastolic function measured by early to atrial filling rate (E:A ratio) with Doppler echocardiography were determined before and after + candoxatrilat and placebo.
Results-+ Candoxatrilat caused a threefold rise of plasma ANF compared with placebo (p < 0005), but there was no significant change in heart rate, blood pressure, or cardiac output. Mean right atrial pressure fell from 6-7 to 4-7 mm Hg (NS) and pulmonary artery wedge pressure fell from 9-2 to 6'7 Approval was obtained from the local hospital ethical committee and all patients gave informed consent to the study.
STUDY DESIGN
Diuretic treatment was withdrawn two days before the study and all other medications were withdrawn for at least seven days. Patients were studied on four consecutive days in hospital and a standard diet containing 150 mmol of sodium was maintained throughout. All studies began at 7.00 am with an oral fluid load of 200 ml of iced water, taken after voiding urine. Fluid balance was maintained during the subsequent 10 hours by voiding every hour and replacing urinary losses by drinking water.
+Candoxatrilat was diluted in 20 ml of isotonic saline before intravenous infusion for 20 minutes. The neutral endopeptidase inhibitor or vehicle alone was given after the second hourly urine collection in a single blind fashion. Blood samples were taken at zero, one, two, four, and eight hours after dosing through positioned to obtain the highest diastolic transmitral flow velocities. Doppler spectral profiles were recorded on video tape and analysed by integral software. The peak velocities during early and atrial diastolic filling were each averaged over 10 consecutive cardiac cycles. The E:A ratio, a Doppler index of left ventricular diastolic function,'2 13 was then calculated as peak early filling velocity:peak latefilling velocity. DOSING 
SCHEDULE
This was the first study of + candoxatrilat in patients with chronic heart failure and therefore a wide range of doses, all ofwhich had previously been well tolerated in normal human volunteers, was given. Each dose of + candoxatrilat or placebo was given on a separate day at around 9.00 am. For safety reasons, initial doses were small and larger doses were administered only if these were well tolerated. Patients were randomised in pairs with the first pair receiving active doses of 10 mg then 20 mg alternating with vehicle alone in random order. Similarly, the second pair of patients were given 50 mg then 100 mg, and the final pair received 200 mg and 400 mg. Because invasive haemodynamic measurements were only made on the final two study days, only the results from these days are shown-that is, doses of 20 mg, 100 mg, and 400 mg. (6) 78 (8) 76 (5) 79 (8) SBP (mm Hg) 116 (8) 115 (7) 114 (6) 116 (7) 117 (8) DBP (mm Hg) 76 (5) 78 (4) 74 (4) 76 (4) 76 (4) CO (1/ which had been preconstricted with noradrenaline, showed significant (70%) dilatation with a low concentration of ANF.'5 Therefore we think that the fall in right and left ventricular filling pressures that we have found after + candoxatrilat, and others have seen during infusion of ANF, is due to dilatation of venous capacitance vessels, although we cannot exclude the possibility of a small fall in effective blood volume. This study has some limitations. The small number of patients studied leads to a risk of type II error, although the cross over design compensates to some extent. The patients received increasing doses of + candoxatrilat because we wished to establish the safety of each dose before progressing to a higher dose. This was unavoidable as it was the first study of an endopeptidase inhibitor in patients with heart failure. Consequently only two patients received each dose, so it was necessary to pool the data from different doses to make statistical comparisons possible. We have already discussed the limitations of the Doppler measurement of diastolic function used in this study.
In conclusion, we have shown that inhibition of neutral endopeptidase by ± candoxatrilat leads to a threefold rise in concentration of plasma ANF in mild heart failure. The principal acute haemodynamic effect is a fall in cardiac filling pressures. This was not due to an improvement in left ventricular systolic or diastolic performance, but suggests a peripheral vascular effect.
